Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
The investigators intend to examine the effects of ocrelizumab use in African American
 multiple sclerosis disease course compared to Caucasian disease course utilizing imaging
 measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography
 (OCT-A)..
Multiple sclerosis (MS) is a disease of the central nervous system (CNS). Several lines of
 evidence suggest that MS is an autoimmune disease with both T and B-cell activity leading to
 CNS inflammation which results in demyelinating injury. Ocrelizumab was FDA approved in March
 2017 for relapsing remitting (RRMS) and primary progressive multiple sclerosis (PPMS) by
 depleting B cells. It has shown to be effective in reducing the annualized relapse rate,
 decreasing disability progression, and reducing the number of new and active MRI brain
 lesions.

 Previous research studies have reported a more aggressive course in African Americans with
 MS, more lesions on the MRI scan, and more severe injury to layers of the eye (specifically
 in the retina) compared to Caucasians.

 This is a novel study investigating the effect of ocrelizumab in African American relapsing
 multiple sclerosis (RMS) patients compared to Caucasian RMS patients using imaging measures,
 specifically multimodal magnetic resonance imaging (MRI) and optical coherence
 tomography-angiography (OCTA). This is a non-drug intervention study; therefore, patients who
 are recruited will have already decided to make ocrelizumab their disease-modifying therapy
 before enrollment. The study will recruit 86 (including 6 potential screen fails) patients in
 total (40 African American patients and 40 Caucasian patients who are matched by age, sex,
 disease duration, and disease disability. The study will consist of 5 visits in six-month
 intervals across two years.
Inclusion Criteria:

 1. Patients who have chosen to start ocrelizumab and for whom ocrelizumab is determined
 to be the most appropriate standard-of-care disease modifying therapy (DMT) by the
 treating neurologist.

 2. May be treatment naive, or had suboptimal response to no more than one DMT after an
 adequate course of treatment (defined as treatment duration of 6+ months).

 3. Age 18 to 60 years old.

 4. Ethnicity: self-identified as African American or Caucasian.

 5. Clinically definite relapsing remitting multiple sclerosis (RRMS) per 2017 revised
 McDonald criteria.

 6. EDSS from 0 to 6 (inclusive) at baseline visit.

 7. Able to give informed consent.

 8. Able to have MRI scans.

 Exclusion Criteria:

 1. Treatment with another monoclonal antibody, including but not limited to natalizumab,
 alemtuzumab, daclizumab.

 2. Failed 2 or more DMTs.

 3. Treatment with immunosuppressant agents, such as chemotherapeutic agents.

 4. Claustrophobia.

 5. Allergy to contrast.

 6. Significant medical problems that the PI determines will interfere with the conduct of
 the study.

 7. Relapse or use of corticosteroids within 30 days prior to baseline visit.

 8. Pregnancy.

 9. History of kidney or liver insufficiency.

 10. History of malignancy.